Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Micafungin
Drug ID BADD_D01455
Description Micafungin is an antifungal drug. It belongs to the antifungal class of compounds known as echinocandins and exerts its effect by inhibiting the synthesis of 1,3-beta-D-glucan, an integral component of the fungal cell wall.
Indications and Usage Indicated for the treatment of candidemia, acute disseminated candidiasis, and certain other invasive Candida infections, as well as esophageal candidiasis, and prophylaxis of Candida infections in patients undergoing hematopoietic stem cell transplantation. Micafungin is also used as an alternative for the treatment of oropharyngeal candidiases and has been used with some success as primary or salvage therapy, alone or in combination with other antifungals, for the treatment of invasive aspergillosis. Indicated for the prophylaxis of Candida infections in patients undergoing hematopoietic stem cell transplantation.
Marketing Status approved; investigational
ATC Code J02AX05
DrugBank ID DB01141
KEGG ID D08218
MeSH ID D000077551
PubChem ID 477468
TTD Drug ID D06TOE
NDC Product Code 16714-301; 70710-1725; 60505-6120; 70771-1683; 60505-6119; 70771-1684; 42023-229; 16714-164; 70710-1724; 42023-230
UNII R10H71BSWG
Synonyms Micafungin | FK 463 | FK463 | FK-463 | Micafungin Sodium | Mycamine
Chemical Information
Molecular Formula C56H71N9O23S
CAS Registry Number 235114-32-6
SMILES CCCCCOC1=CC=C(C=C1)C2=CC(=NO2)C3=CC=C(C=C3)C(=O)NC4CC(C(NC(=O)C5C(C(CN5C(=O)C(NC (=O)C(NC(=O)C6CC(CN6C(=O)C(NC4=O)C(C)O)O)C(C(C7=CC(=C(C=C7)O)OS(=O)(=O)O)O)O)C(C C(=O)N)O)C)O)O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Acute generalised exanthematous pustulosis11.07.01.018; 10.01.01.034; 23.03.10.002; 12.03.01.0050.000150%Not Available
Deep vein thrombosis24.01.02.003--Not Available
Acute coronary syndrome24.04.04.011; 02.02.02.015--Not Available
Infusion related reaction12.02.05.009; 10.01.01.017; 08.01.03.002--
Lymphatic disorder01.09.01.003--Not Available
Foetor hepaticus09.01.05.006; 07.01.06.026--Not Available
Musculoskeletal discomfort15.03.04.001--Not Available
Transaminases increased13.03.04.036--Not Available
Haemorrhage24.07.01.0020.000150%Not Available
Infusion site inflammation12.07.05.020; 08.02.05.020--Not Available
Toxic skin eruption12.03.01.073; 23.03.05.003; 10.01.01.008--Not Available
Angiopathy24.03.02.007--Not Available
Blood alkaline phosphatase increased13.04.02.004--
Drug resistance08.06.01.0050.000449%Not Available
Cardiac disorder02.11.01.003--Not Available
Connective tissue disorder10.04.04.026; 15.06.01.006--Not Available
Infestation23.11.01.002; 11.09.01.001--Not Available
Inflammation10.02.01.089; 08.01.05.007--Not Available
Malnutrition14.03.02.004--Not Available
Mediastinal disorder22.09.03.001--Not Available
Mental disorder19.07.01.002--Not Available
Decreased appetite14.03.01.005; 08.01.09.028--
Blood disorder01.05.01.004--Not Available
Autoimmune disorder10.04.04.003--
Hepatobiliary disease09.01.08.003--Not Available
Renal impairment20.01.03.010--Not Available
Bone marrow failure01.03.03.0050.000150%
Haematological malignancy16.21.01.002; 01.13.01.003--Not Available
Liver injury12.01.17.012; 09.01.07.022--Not Available
Brain injury19.07.03.007; 17.11.01.0030.000150%Not Available
The 6th Page    First    Pre   6 7    Next   Last    Total 7 Pages